Market Research Report
Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition): Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, specific BET, DUB and other inhibitors), Therapeutic Areas
|Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition): Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, specific BET, DUB and other inhibitors), Therapeutic Areas|
Published: March 31, 2021
Content info: 330 Pages
Delivery time: 1-2 business days
Targeted Protein Degradation Market:
Focus on Technology Platforms and Therapeutics (2nd Edition): Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, specific BET, DUB and other inhibitors), Therapeutic Areas (Neurological Disorders, Oncological Disorders and Others), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and Rest of the World), 2021-2030.
Targeted protein degradation is a revolutionary pharmacological concept that presents viable drug development opportunities and is anticipated to introduce a new paradigm in modern therapeutic interventions. Due to various reasons, conventional drugs / therapies have been limited in terms of their capability to target certain proteins of pathological significance. Presently, medical researchers engaged in the development of bifunctional protein degrader-based interventions claim that this upcoming class of drugs is capable of targeting biomolecules in the human proteome, which were previously considered undruggable. The concept of targeted protein degradation revolves around the use of small molecule leads, which are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target biomolecule. In other words, protein degraders regulate biological pathways by selectively downregulating a target protein by degrading them; this process has been shown to be robust, more sensitive to drug-resistant targets and can regulate cellular functions that are not dependent on enzyme action. Moreover, drugs designed based on this relatively novel concept, have been shown to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, compared to traditional enzyme inhibitors. As a result, this upcoming class of drugs has garnered significant interest within the medical science community. In fact, the growing popularity of targeted protein degradation is evident in the USD 5 billion in capital investments made into companies engaged in this field of research, since 2014.
Proteolysis targeting chimera (PROTAC), developed by Hashimoto Laboratory in 2008, was the first targeted protein degrader. The incessant efforts of researchers involved in this domain have resulted in significant progress towards understanding the physiochemical and biological properties of such bifunctional molecules. Presently, there are several other types of targeted protein degraders and molecular glues, which have been / are being developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. It is worth noting that the R&D efforts in this field are supported by DNA-encoded libraries and other in silico hit discovery and characterization tools. In the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Additionally, several big pharma players are also actively involved in this field, evaluating proprietary protein degrader-based therapeutic leads. The market has also witnessed substantial partnership activity over the last few years, with several technology developers involved in high-value licensing deals. Although, there are no approved protein degrader-based drugs / therapy products, the market is poised to witness healthy growth over the next decade.
The 'Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition), 2021-2030: Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, and specific BET and DUB inhibitors, and other inhibitors), Therapeutic Area (Neurological Disorders, Oncological Disorders, and Other Therapeutic Areas), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)' report features an extensive study of the current and future potential of protein degraders, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities of novel technologies for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided informed estimates on the evolution of the market over the period 2021-2030. For estimating the future market opportunities for technology providers, we have considered the likely licensing deal structures and agreements that are likely to be established in the foreseen future. The future opportunity within the targeted protein degradation market has been segmented across (A) different types of protein degraders (degronimids, PROTACs, SARDs / SERDs, Specific BET and DUB Inhibitors, and other inhibitors), (B) therapeutic areas (oncological disorders, neurological disorders, and other therapeutic areas), (C) route of administration (oral route, intravenous route, and other routes), and (D) key geographical regions (North America, Europe and Asia Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of targeted protein degradation-based drugs market and its likely evolution in the short-mid- term and long term.
Chapter 3 provides an introduction to protein homeostasis, including a discussion on the UPS for intracellular protein degradation and turnover. It presents an elaborate discussion on the structure and function of ubiquitin, various components of the UPS and key steps involved in the UPS-based protein degradation. Further, the chapter provides an overview of the concept of targeted protein degradation, including details on various protein degraders and their associated pathways and mechanisms of action. The chapter also includes a discussion on the historical evolution, importance, advantages and challenges associated with the use of targeted protein degradation as a therapeutic principle. In addition, the chapter describes the key growth drivers and roadblocks related to targeted protein degraders, offering insights on the upcoming trends in the domain.
Chapter 4 includes information on more than 155 targeted protein degraders that are currently being evaluated in different stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules, based on their types of protein degraders (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indications, key therapeutic areas, types of target proteins, target enzymes (if available), target signaling pathways (if available), mechanisms of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and company size.
Chapter 5 provides an overview of the overall landscape of the targeted protein degradation enabling technologies, including an analysis based on type of degrader. In addition, the chapter features a list of technology developers and an analysis based on several parameters, such as such as year of establishment, company size, and location of headquarters.
Chapter 6 features elaborate profiles of prominent players engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), details on their respective lead drug candidates, recent development and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history. Further, the chapter includes tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the developer (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.
Chapter 7 provides a detailed analysis of completed, ongoing and planned clinical studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.
Chapter 8 provides an analysis of more than 770 grants that were awarded to research institutes engaged in target protein degradation, in the period between 2017 and 2020 based on the important parameters, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, study section, popular NIH departments, study section, type of recipient organizations, popular recipient organizations, popular program officers and regional distribution.
Chapter 9 provides information on certain recent publications that we came across during our research on target protein degradation. This chapter highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of protein degrader, biological target, associated ubiquitin enzyme, number of publications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal).
Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to target protein degradation, since 2018, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
Chapter 11 provides an analysis of KOLs in the field of targeted protein degradation. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation of a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criterion, which was based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
Chapter 12 features an elaborate discussion and analysis of collaborations and partnerships that have been inked between different players in this market since 2014. It includes a brief description of various types of partnership models (such as research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to targeted protein degraders. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.
Chapter 13 provides information on funding instances and investments that have been made within the targeted protein degradation domain. The chapter includes details on the capital (in the form of seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies in the period 2014-2020, highlighting the growing interest of the venture capital community and other strategic investors in this domain.
Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of novel technologies designed for the development of targeted protein degraders till the year 2030, based on licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across (A) different types of protein degraders (degronimids, PROTACs, SARDs / SERDs, Specific BET and DUB Inhibitors, and other inhibitors), (B) therapeutic areas (oncological disorders, neurological disorders, and other therapeutic areas), (C) route of administration (oral route, intravenous route, and other routes), and (D) key geographical regions (North America, Europe and Asia Pacific).
Chapter 15 provides deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.
Chapter 16 is a collection of interview transcripts of discussions held with key stakeholders in this market.
Chapter 17 is a summary of the overall report. It presents the key takeaways and offers our independent opinion related to the research and analysis described in the previous chapters.
Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 19 is an appendix, which contains the list of companies and organizations.